TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Clinical trial NCT05002998 · COMPLETED

Trial details

NCT number: NCT05002998
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Thyroid Eye Disease

Start date: 2021-09-16
Primary completion: 2025-12-19
Enrollment: 313

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.